A design for prescription-event monitoring in Japan (J-PEM)

Pharmacoepidemiology and Drug Safety

Volumn 8, Issue 6, 1999, Pages 447-456

  Kiyoshi Kubota, M D ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cohort study; Pharmacovigilance; Postmarking suveillance; Prescription event monitoring

Indexed keywords

DRUG;

ARTICLE; DRUG INFORMATION; DRUG MONITORING; DRUG USE; HUMAN; JAPAN; METHODOLOGY; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 0344286132     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199910/11)8:6<447::AID-PDS446>3.0.CO;2-I     Document Type: Article

References (39)

1. Ohe, K. and Kaihara, S. Implementation of HL7 to client-server hospital information system (HIS) in the University of Tokyo Hospital. J. Med. Systems 1996; 20: 197-205.
2. Yoshihara, H. Status quo and future prospects of the total hospital information system on a Japanese medical college. J. Med. Systems 1994; 18: 229-240.
3. Ogura, H., Sagara, E., Iwata, M., et al Online support functions of prescription order system and prescription audit in an integrated hospital information system. Med. Informatics 1988; 13: 161-169.
4. Campbell, J. C. and Ikegami, N. The Art of Balance in Health Policy Maintaining Japan's Low-cost Egalitarian System, Cambridge University Press, Cambridge, 1998.
5. Inman, W. H. W., Rawson, N. S. B. and Wilton, L. V. Prescription-event monitoring. In: Monitoring for Drug Safety, 2nd edn. Inman, W. H. W. (Ed.), MTP Press, Lancaster, 1986, pp. 213-235.
6. Rawson, N. S. B., Pearce, G. L. and Inman, W. H. W. Prescription-event monitoring: methodology and recent progress. J. Clin. Epidemiol. 1990; 43: 509-522.
7. Mann, R. D. Prescription-event monitoring -recent progress and future horizons. Br. J. Clin. Pharmacol. 1998; 46: 195-201.
8. Inman, B. 30 years in postmarketing surveillance. A personal perspective. Pharmacoepidem. Drug Safe. 1993; 2: 239-258.
9. Kubota, K. and Inman, W. H. W. Terminology in prescription-event monitoring. Eur. J. Clin. Pharmacol. 1994; 46: 497-500.
10. Kubota, K., Pearce, G. L. and Inman, W. H. W. Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur. J. Clin. Pharmacol. 1995; 48: 1-7.
11. Kubota, K., Kubota, N., Pearce, G. L., Prescott, P. and Mann, R. D. Signalling drug-induced rash with 36 drugs recently marketed in the United Kingdom and studied by prescription-event monitoring. Int. J. Clin. Pharmacol. Ther. 1995; 33: 219-225.
12. Andrew, J. E., Prescott, P., Smith, T. M. F., Inman, W. H. W. and Kubota, K. Testing for adverse reactions using prescription event monitoring. Stat. Med. 1996; 15: 987-1002.
13. Kubota, K., Kubota, N., Pearce, G. L. and Inman, W. H. W. ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years. Eur. J. Clin. Pharmacol. 1996; 49: 431-437.
14. Mann, R. D., Kubota, K., Pearce, G. and Wilton, L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15497 patients J. Clin. Epidemiol. 1996; 49: 247-250.
15. Edwards, J. G., Inman, W. H. W., Pearce, G. and Kubota, K. Drug safety monitoring of 12692 patients treated with fluoxetine. Human Psychopharmacol. 1997; 12: 127-137.
16. Edwards, I. R. and Biriell, C. Harmonisation in pharmacovigilance. Drug Safe. 1994; 10: 93-102.
17. Myers, M. W. and Jick, H. Terfenadine and risk of acute liver disease. Br. J. Clin. Pharmacol. 1998; 46: 251-253.
18. Jick, H., Jick, S., Derby, L. E. et al Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-528.
19. Farmer, R. D. T., Lawrenson, R. A., Thompson, C. R., Kennedy, J. G. and Hambleton, I. R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-88.
20. McMahon, A. D., Steinke, D. T., McArlpine, R. R. and MacDonald, T. M. Do H2-receptor antagonists cause acute pancreatitis? Pharmacoepidem. Drug Safe. 1998; 7: 383-388.
21. Day, R. O., Quinn, D. I., Conaghan, P. G. and Tett, S. E. Adverse drug reactions and their measurements in the rheumatic diseases. J. Rheumatol. 1995; 22: 983-988.
22. 2 agonists cause heart failure? Lancet 1998; 352: 1081-1082.
23. 2 agonists and heart failure. Lancet 1998; 352: 1709-1710.
24. Inman, W. and Pearce, G. Prescriber profile and post-marketing surveillance. Lancet 1993; 342: 658-661.
25. Fletcher, R. H., Fletcher, S. W. and Wagner, E. H. Clinical Epidemiology, 3rd edn, Williams & Wilkins, Baltimore, 1996.
26. Inman, W. H. W. Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton. Br. Med. J. 1981; 282: 1216-1217.
27. Medicine Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and The British Pharmaceutical Industry. Guidelines for company-sponsored safety assessment of marketed medicines (SAMM guidelines). Br. J. Clin. Pharmacol. 1994; 38: 95-97.
28. Kaneko, T. Troglitazone (CS-045): A new antidiabetic agent. Hormone Metab. Res. 1997; 29: 203-213.
29. Riddle, M. C. Learning to use troglitazone. Diabetes Care 1998; 21: 1389-1390.
30. Dunn, N. R., Freemantle, S. N., Pearce, G. L. and Mann, R. D. Galactorrhoea with moclobemide. Lancet 1998; 351: 802.
31. 2 agonists. Thorax 1998; 53: 558-562.
32. Levine, M., Walter, S., Lee, H., Haines, T., Holbrook, A. and Moyer, V. User's guides to the medical literature. IV. How to use an article about harm. JAMA 1994; 271: 1615-1619.
33. Jick, H., Rodriguez, L. A. G. and Perez-Gutthann, S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998; 352: 1767-1770.
34. Strom, B. L. How should one perform pharmacoepidemiology studies? Choosing among the available alternatives. In: Pharmacoepidemiology, 2nd edn. Strom, B. L. (Ed.), John Wiley & Sons, New York, 1994, pp. 337-350.
35. Mann, R. D. Adverse reactions and the science of pharmacosurveillance. Eur. Respir. Rev. 1998; 8: 1051-1053.
36. Inman, W. H. W., Rawson, N. S. B., Wilton, L. V., Pearce, G. L. and Speirs, C. J. Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring. Br. Med. J. 1988; 297: 826-829.
37. Speirs, C. J., Dollery, C. T., Inman, W. H. W., Rawson, N. S. B. and Wilton, L. V. Postmarketing surveillance of enalapril. II. Investigation of the potential role of enalapril in deaths with renal failure. Br. Med. J. 1988; 297: 830-832.
38. Inman, W. H. W. PEM News No. 7. Drug Safely Research Unit, Southampton, 1991.
39. Mackay, F. J., Pearce, G. L. and Mann, R. D. Cough and angiotensin II receptor antagonists: Cause or confounding? Br. J. Clin. Pharmacol. 1999; 47: 111-114.